A reduced density of α7-nAChR has been seen post-mortem in patients with Alzheimer's disease (AD) and schizophrenia.3 Therefore, α7-nAChR is assumed to be an important target to treat neurodegenerative and neuropsychiatric diseases. This evidence concerns the gene CHRNA7 and Alzheimer disease.